
Dmitri Sviridov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6398968/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2071-2077.	1.1	392
2	High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus. Circulation, 2009, 119, 2103-2111.	1.6	363
3	Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from Macrophages. PLoS Biology, 2006, 4, e365.	2.6	266
4	Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque. Circulation Research, 2008, 103, 1084-1091.	2.0	251
5	Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1333-1341.	1.1	172
6	Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux. Circulation, 2009, 120, 2095-2104.	1.6	167
7	Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis, 2002, 161, 245-254.	0.4	135
8	HIV infection and high density lipoprotein metabolism. Atherosclerosis, 2008, 199, 79-86.	0.4	127
9	5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 634-641.	1.3	103
10	Antiatherogenic Functionality of High Density Lipoprotein: How Much versus How Gooden-subtitle=. Journal of Atherosclerosis and Thrombosis, 2008, 15, 52-62.	0.9	100
11	Expression of Caveolin-1 Enhances Cholesterol Efflux in Hepatic Cells. Journal of Biological Chemistry, 2004, 279, 14140-14146.	1.6	93
12	HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism: Clinical and Experimental, 2006, 55, 90-95.	1.5	88
13	Asymmetry in the Lipid Affinity of Bihelical Amphipathic Peptides. Journal of Biological Chemistry, 2008, 283, 32273-32282.	1.6	87
14	Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells. PLoS Pathogens, 2019, 15, e1007907.	2.1	86
15	Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis. Diabetes, 2021, 70, 772-787.	0.3	84
16	Cholesterol Efflux Assay. Journal of Visualized Experiments, 2012, , e3810.	0.2	74
17	Lipid rafts as a therapeutic target. Journal of Lipid Research, 2020, 61, 687-695.	2.0	72
18	Structure/Function Relationships of Apolipoprotein A-I Mimetic Peptides. Circulation Research, 2010, 107, 217-227.	2.0	71

2

#	Article	IF	CITATIONS
19	A Mouse Model of Harlequin Ichthyosis Delineates a Key Role for Abca12 in Lipid Homeostasis. PLoS Genetics, 2008, 4, e1000192.	1.5	70
20	HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux. Journal of Lipid Research, 2012, 53, 696-708.	2.0	69
21	The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovascular Research, 2008, 77, 732-739.	1.8	68
22	Efflux of Cellular Cholesterol and Phospholipid to Apolipoprotein A-I Mutants. Journal of Biological Chemistry, 1996, 271, 33277-33283.	1.6	61
23	Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. European Heart Journal, 2012, 33, 657-665.	1.0	60
24	Circulating Nef Induces Dyslipidemia in Simian Immunodeficiency Virus–Infected Macaques by Suppressing Cholesterol Efflux. Journal of Infectious Diseases, 2010, 202, 614-623.	1.9	51
25	Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States. Cell Reports, 2018, 23, 2667-2677.	2.9	51
26	ABCA12 Regulates ABCA1-Dependent Cholesterol Efflux from Macrophages and the Development of Atherosclerosis. Cell Metabolism, 2013, 18, 225-238.	7.2	46
27	HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis. FASEB Journal, 2014, 28, 2828-2839.	0.2	45
28	Targeting Lipid Rafts—A Potential Therapy for COVID-19. Frontiers in Immunology, 2020, 11, 574508.	2.2	45
29	Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. Journal of Lipid Research, 2008, 49, 2312-2322.	2.0	44
30	Lipid rafts and pathogens: the art of deception and exploitation. Journal of Lipid Research, 2020, 61, 601-610.	2.0	43
31	Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis, 2008, 197, 732-739.	0.4	42
32	Identification of a Sequence of Apolipoprotein A-I Associated with the Activation of Lecithin:Cholesterol Acyltransferase. Journal of Biological Chemistry, 2000, 275, 19707-19712.	1.6	41
33	Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae). Biochemical Journal, 2001, 358, 79-86.	1.7	41
34	Interaction of pathogens with host cholesterol metabolism. Current Opinion in Lipidology, 2014, 25, 333-338.	1.2	40
35	Cytomegalovirus Restructures Lipid Rafts via a US28/CDC42-Mediated Pathway, Enhancing Cholesterol Efflux from Host Cells. Cell Reports, 2016, 16, 186-200.	2.9	39
36	Delineation of the Role of Pre-β1-HDL in Cholesterol Efflux Using Isolated Pre-β1-HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1482-1488.	1.1	31

#	Article	IF	CITATIONS
37	The effect of HIV infection on atherosclerosis and lipoprotein metabolism: A one year prospective study. Atherosclerosis, 2013, 229, 206-211.	0.4	31
38	Prion Infection Impairs Cholesterol Metabolism in Neuronal Cells. Journal of Biological Chemistry, 2014, 289, 789-802.	1.6	31
39	Small GTPase ARF6 Regulates Endocytic Pathway Leading to Degradation of ATP-Binding Cassette Transporter A1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2292-2303.	1.1	31
40	HIV-1 Protein Nef Inhibits Activity of ATP-binding Cassette Transporter A1 by Targeting Endoplasmic Reticulum Chaperone Calnexin. Journal of Biological Chemistry, 2014, 289, 28870-28884.	1.6	30
41	Comorbidities of HIV infection. Aids, 2020, 34, 1-13.	1.0	30
42	Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae). Biochemical Journal, 2001, 358, 79.	1.7	29
43	Single session exercise stimulates formation of preβ1-HDL in leg muscle. Journal of Lipid Research, 2003, 44, 522-526.	2.0	28
44	Elevated HDL Cholesterol is Functionally Ineffective in Cardiac Transplant Recipients: Evidence for Impaired Reverse Cholesterol Transport. Transplantation, 2006, 81, 361-366.	0.5	28
45	An Apolipoprotein A-I Mimetic Peptide Designed with a Reductionist Approach Stimulates Reverse Cholesterol Transport and Reduces Atherosclerosis in Mice. PLoS ONE, 2013, 8, e68802.	1.1	28
46	HIV infection induces structural and functional changes in high density lipoproteins. Atherosclerosis, 2015, 243, 19-29.	0.4	27
47	High-density lipoprotein mimetics: promises and challenges. Biochemical Journal, 2015, 472, 249-259.	1.7	25
48	Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts. MBio, 2020, 11, .	1.8	24
49	The Role of Different Regions of ATP-Binding Cassette Transporter A1 in Cholesterol Efflux. Biochemistry, 2007, 46, 9388-9398.	1.2	22
50	Anti-Inflammatory Functions of Apolipoprotein A-I and High-Density Lipoprotein Are Preserved in Trimeric Apolipoprotein A-I. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 41-49.	1.3	21
51	Interaction Between HIV-1 Nef and Calnexin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1758-1771.	1.1	21
52	Apolipoprotein A-I Mimetic Peptides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1301-1306.	1.1	21
53	Statins and Metabolism of High Density Lipoprotein. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 215-221.	0.4	20
54	HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study. PLoS ONE, 2019, 14, e0215620.	1.1	20

#	Article	IF	CITATIONS
55	Modification of lipid rafts by extracellular vesicles carrying HIV-1 protein Nef induces redistribution of amyloid precursor protein and Tau, causing neuronal dysfunction. Journal of Biological Chemistry, 2020, 295, 13377-13392.	1.6	20
56	Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection. Biochemical and Biophysical Research Communications, 2012, 419, 95-98.	1.0	19
57	Production of Mature Human Apolipoprotein A-I in a Baculovirus–Insect Cell System: Propeptide Is Not Essential for Intracellular Processing but May Assist Rapid Secretion. Analytical Biochemistry, 1997, 253, 253-258.	1.1	18
58	HIV and Cardiovascular Disease: Contribution of HIV-Infected Macrophages to Development of Atherosclerosis. PLoS Medicine, 2007, 4, e43.	3.9	18
59	Fetal inhibition of inflammation improves disease phenotypes in harlequin ichthyosis. Human Molecular Genetics, 2015, 24, 436-449.	1.4	17
60	Lipid metabolism in patients infected with Nef-deficient HIV-1 strain. Atherosclerosis, 2016, 244, 22-28.	0.4	16
61	Impact of freezing on high-density lipoprotein functionality. Analytical Biochemistry, 2008, 379, 213-215.	1.1	15
62	Cholesterol transport between red blood cells and lipoproteins contributes to cholesterol metabolism in blood. Journal of Lipid Research, 2020, 61, 1577-1588.	2.0	15
63	Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 376-383.	1.3	14
64	Biology of Lipid Rafts: Introduction to the Thematic Review Series. Journal of Lipid Research, 2020, 61, 598-600.	2.0	14
65	ABCA12 regulates insulin secretion from βâ€cells. EMBO Reports, 2020, 21, e48692.	2.0	13
66	Cholesterol Efflux-Independent Modification of Lipid Rafts by AIBP (Apolipoprotein A-I Binding) Tj ETQq0 0 0 rgB	T /Qverloc	k 10 Tf 50 30
67	Natural mutations of apolipoprotein A-I impairing activation of lecithin:cholesterol acyltransferase. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 72-76.	1.2	10
68	Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. PLoS ONE, 2020, 15, e0237739.	1.1	10
69	Characterization of the Maturation of Human Pro-apolipoprotein A-I in an in Vitro Model. Biochemistry, 2001, 40, 3101-3108.	1.2	9
70	Inhibition of Extracellular Cyclophilins with Cyclosporine Analog and Development of Atherosclerosis in Apolipoprotein E–Deficient Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 490-495.	1.3	9
71	Effectivity of Expression of Mature Forms of Mutant Human Apolipoprotein A-I. Protein Expression and Purification, 1999, 17, 231-238.	0.6	8
72	Short Communication: Accumulation of Neutral Lipids in Liver and Aorta of Nef-Transgenic Mice. AIDS Research and Human Retroviruses, 2017, 33, 57-60.	0.5	8

#	Article	IF	CITATIONS
73	Maturation of apolipoprotein A-I: unrecognized health benefit or a forgotten rudiment?. Journal of Lipid Research, 2009, 50, 1257-1258.	2.0	7
74	Abundance of Nef and p-Tau217 in Brains of Individuals Diagnosed with HIV-Associated Neurocognitive Disorders Correlate with Disease Severance. Molecular Neurobiology, 2022, 59, 1088-1097.	1.9	7
75	Low-Density Lipoprotein Receptor and Apolipoprotein A-I and B Expression in Human Enterocytes. Digestion, 2003, 67, 67-70.	1.2	6
76	Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Bioscience Reports, 2018, 38, .	1.1	6
77	Trained Immunity and HIV Infection. Frontiers in Immunology, 0, 13, .	2.2	6
78	Direct interaction between ABCA1 and HIV-1 Nef: Molecular modeling and virtual screening for inhibitors. Computational and Structural Biotechnology Journal, 2021, 19, 3876-3884.	1.9	5
79	Analysis of ABCA1 and Cholesterol Efflux in HIV-Infected Cells. Methods in Molecular Biology, 2016, 1354, 281-292.	0.4	5
80	Global functional knockdown of ATP binding cassette transporter A1 stimulates development of atherosclerosis in apoE K/O mice. Biochemical and Biophysical Research Communications, 2011, 412, 446-449.	1.0	4
81	Cdc42 – A tryst between host cholesterol metabolism and infection. Small GTPases, 2018, 9, 237-241.	0.7	4
82	Cyclophilins in Atherosclerosis: A New Therapeutic Target?. Current Pharmaceutical Design, 2013, 19, 5904-5908.	0.9	4
83	Isolation of Lipid Rafts from Cultured Mammalian Cells and Their Lipidomics Analysis. Bio-protocol, 2020, 10, e3670.	0.2	4
84	High-Density Lipoprotein ââ,¬â€œ A Hero, a Mirage, or a Witness?. Frontiers in Cardiovascular Medicine, 2014, 1, 9.	1.1	3
85	Non-linear optical imaging of atherosclerotic plaques in the context of SIV and HIV infection prominently detects crystalline cholesterol esters. PLoS ONE, 2021, 16, e0251599.	1.1	2
86	Introduction. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 700-702.	0.9	1
87	Fenofibrate, homocysteine, cholesterol efflux and primum non nocere. Atherosclerosis, 2011, 219, 24-25.	0.4	1
88	Lipidomic dataset of plasma from patients infected with wild type and nef-deficient HIV-1 strain. Data in Brief, 2016, 6, 168-175.	0.5	1